Is RPG LifeScience. overvalued or undervalued?
As of November 3, 2025, RPG LifeScience is considered overvalued with a PE ratio of 36.14, a Price to Book Value of 7.59, and an EV to EBITDA ratio of 25.22, indicating a premium compared to peers like Sun Pharma and Cipla, while its recent performance shows a one-year return of -7.32% against the Sensex's 5.34%.
As of 3 November 2025, RPG LifeScience has moved from a fair to an expensive valuation grade. The company appears to be overvalued based on its current financial metrics. The PE ratio stands at 36.14, while the Price to Book Value is 7.59, and the EV to EBITDA ratio is 25.22. These ratios indicate a premium valuation compared to its peers.In comparison to its industry peers, RPG LifeScience's PE ratio is higher than Sun Pharma's 35.62 and significantly above Cipla's attractive PE of 22.44. The PEG ratio of 0.85 suggests that, despite the high valuation, the growth expectations may not justify the current price. Additionally, while the company has shown strong returns over the past three years at 177.36%, its one-year return of -7.32% contrasts with the Sensex's 5.34%, reinforcing the notion that it may be overvalued at this time.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
